Compare Micron Technology, Inc. (MU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Micron Technology, Inc. trades at $1,016 (market cap $1.13T), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Micron Technology, Inc. pays a 0.05% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MU | XBI | |
|---|---|---|
Market Cap | $1.13T | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $1.21K | $169.55 |
52-Week Low | $140.00 | $93.43 |
Enterprise Value | $1.11T | — |
Dividend Yield | 0.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% today but remains in a strong uptrend, supported by bullish technical signals and robust fundamentals. The company reported Q1 2026 EPS of $25.11, beating estimates by 20%, with revenue surging to $37.38 billion in 2025. Operating cash flow hit $17.53 billion, while analyst consensus is strongly bullish with an 82.9% buy rating and a $1,550 price target.
Outlook is positive due to AI-driven memory demand, with 2026 revenue projected at $90.3 billion. Risks include memory market cyclicality and supply constraints, but Micron's margin expansion and institutional support suggest further upside for investors seeking growth in semiconductor equities.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
